INNEXUS BIOTECHNOLOGY GETS PATENT GRANTS IN EUROPE.
InNexus Biotechnology Inc., (OTC Bulletin Board: IXSBF; TSX
VENTURE: IXS; http://www.ixsbio.com/), British Columbia, Canada, a drug
development company commercializing the next generation of . . .
GENEREX BIOTECHNOLOGY AWARDED NEW DRUG DELIVERY PATENT.
Generex Biotechnology Corporation (Nasdaq:GNBT), Worcester, Mass.,
a leader in drug delivery for metabolic diseases through the inner
lining of the mouth, has received a new patent in Australia.
. . .
DEBIOPHARM/EPFL TO IDENTIFY INHIBITORS FOR CANCER
TREATMENT.
Debiopharm Group (Debiopharm), Lausanne, Switzerland, a global
independent biopharmaceutical development specialist focusing on serious
medical conditions and particularly oncology, has announced . . .
GPC BIOTECH MARKETING AUTHORIZATION APPLICATION
WITHDRAWN.
GPC Biotech AG (Frankfurt Stock Exchange: GPC, NASDAQ: GPCB)
reported that the company has been informed by its partner for
satraplatin in Europe that they plan to withdraw the . . .
ACCELERA RECOGNIZED FOR DEVELOPMENT OF FEXINIDAZOLE.
The development of fexinidazole for the treatment of African
trypanosomiasis, commonly known as "sleeping sickness", by
DNDi (Drugs for Neglected Diseases initiative), along with . . .
FDA APPROVES CEPHALON TREANDA TO TREAT NON-HODGKINS
LYMPHOMA.
Cephalon, Inc., (Nasdaq: CEPH) has announced that the U.S. Food and
Drug Administration (FDA) has approved TREANDA(r) (bendamustine
hydrochloride) for Injection for the treatment of patients with . . .
CYTOPIA BEGINS SECOND PHASE II STUDY IN BRAIN CANCER.
Cytopia Limited, Melbourne, Australia, is commencing enrolment for
its Phase Ib/II study of CYT997, the company's novel
vascular-disrupting anticancer agent, in patients with an aggressive
form of . . .
FDA ACCEPTS DATA FROM BRIDGE'S BEIJING FACILITY.
Bridge Laboratories, Gaithersburg, Md., has announced that the FDA
has accepted data submitted from its Beijing facility on behalf of a US
biotech client. The Good Laboratory Practices (GLP) . . .
OREXO/PROSTRAKAN EXTEND LICENSING PACT FOR RAPINYL
(ABSTRAL).
Orexo AB (OMX: ORX), the Swedish pharmaceutical company, and
ProStrakan Group plc, the Scottish-based international specialty
pharmaceutical company, have extended their existing European . . .
SUBJECTS ENROLLED IN PRESEPT COLORECTAL CANCER SCREENING.
Epigenomics AG (Frankfurt:ECX), a molecular diagnostics company
focusing on the development and commercialization of products for cancer
detection based on DNA methylation, has announced the . . .
EXIQON REPORTS POSITIVE CLINICAL DATA FROM EORTC TRIAL.(Clinical
report)
The European Organization for Research and Treatment of Cancer
(EORTC) has undertaken a multi-institutional prospective randomized
clinical trial on 719 late stage epithelial ovarian cancer . . .
IS COST CONTAINMENT IMPACTING PHARMACEUTICAL INNOVATION?
With the costs of providing healthcare spiraling, governments and
payers across the seven major markets are implementing cost-cutting
initiatives in an effort to combat these escalating healthcare . . .
YAMAGATA FUJITSU ORDERS IMPRIO HD2200 NANOPATTERNING
SYSTEM.
Molecular Imprints, Inc., Austin, Texas, the market and technology
leader for nanopatterning systems and solutions, has announced that
Yamagata Fujitsu has placed an order for its newly introduced . . .
EDEN BIODESIGN/HUMAN GENOME SCIENCES SIGN PACT.(Company
overview)
Eden Biodesign Ltd., an expert provider of biopharmaceutical
process development and cGMP manufacturing services, has entered into a
marketing services agreement with Human Genome Sciences, Inc. . . .
BIOTAGE LAUNCHES NEW 24 WELL PYROSEQUENCING SYSTEM.
Pyrosequencing AB, a subsidiary of Biotage AB, Uppsala, Sweden, has
announced the launch of PyroMark(TM)Q24 the latest in the range of
Pyrosequencing(R) Systems. This new high-performance platform . . .
QRXPHARMA/UNIV. OF ALABAMA COLLABORATE FOR PARKINSON'S
RESEARCH.
QRxPharma Limited (ASX:QRX and OTCQX:QRXPY), a clinical-stage
specialty pharmaceutical company focused on the development and
commercialisation of therapies for pain and central nervous . . .
AVANTOGEN'S HAWAII BIOTECH GETS WALTER REED TRIAL
SUPPORT.
Avantogen Ltd (ASX: ACU) has announced additional support for the
Dengue vaccine program developed by Hawaii Biotech Inc, in which
Avantogen holds a significant investment stake.
The Dengue . . .
CYTOPIA APPOINTS STUDY CHAIRMAN FOR JAK2 CLINICAL TRIAL.
Cytopia Limited (ASX:CYT) has appointed Dr Ayalew Tefferi,
Professor of Medicine and Hematology at the Mayo Clinic College of
Medicine, as Clinical Study Chair for the company's Phase I/II
study in . . .
EUROPEAN COMMISSION APPROVES SHORTENED HEPATITIS C
TREATMENT.
Roche has announced that the European Commission has approved a
shortened, 16-week course of treatment with Pegasys (peginterferon
alfa-2a (40 KD)) plus Copegus (ribavirin) for certain hepatitis . . .
VICAL LICENCEE ANGES MG FILES NDA IN JAPAN FOR
COLLATEGENE.
Vical Incorporated (NASDAQ:VICL), San Diego, Calif., has announced
the company's licensee, AnGes MG, Inc., reported submission on of a
New Drug Application (NDA) to the Japanese Ministry of Health, . . .
|
|